Brands: Absorica · Absorica Ld · Amnesteem · Isotretinoin
Average across 34 priced NDCs. A benchmark of pharmacy acquisition cost - not a retail quote.
Prescriptions dispensed under Medicaid (fee-for-service + managed care), summed nationally. The closest free proxy to sales volume - Medicaid only, not all-payer.
US labelers as registered with FDA. Repackagers relabel another company's product; share* is of listed packages, not sales.
| Labeler | Type | Packages | Status |
|---|---|---|---|
| SUN PHARMACEUTICAL INDUSTRIES, INC. | generic | 16 | SUPPLYING |
| Zydus Lifesciences Limited | generic | 13 | SUPPLYING |
| Zydus Pharmaceuticals USA Inc. | generic | 13 | SUPPLYING |
| Aurobindo Pharma Limited | generic | 6 | SUPPLYING |
| Actavis Pharma, Inc. | generic | 6 | SUPPLYING |
| Amneal Pharmaceuticals LLC | generic | 6 | SUPPLYING |
| Mylan Pharmaceuticals Inc. | generic | 4 | SUPPLYING |
Shortages, recalls, and registration changes attached to this drug concept.
Failed Dissolution Specifications — Recalling firm: MYLAN PHARMACEUTICALS INC — Nationwide within the United States
Superpotent and Subpotent — Recalling firm: Teva Pharmaceuticals USA, Inc — FL, OH, PR & MS
Superpotent and Subpotent — Recalling firm: Teva Pharmaceuticals USA, Inc — FL, OH, PR & MS
Superpotent Drug: The 3-month stability result for assay was found to be above specification limit — Recalling firm: Teva Pharmaceuticals USA, Inc — Nationwide in the USA
Subpotent Drug: Isotretinoin content results were lower than the specification limit obtained during routing product monitoring. — Recalling firm: Sun Pharmaceutical Industries, Inc. — Nationwide in the USA
Incorrect/Undeclared Excipients: Product contains undeclared FD&C Yellow No. 5 in the capsule shell. — Recalling firm: Ranbaxy Inc. — Nationwide
